Targeting the immune system to treat hypertension: Where are we?

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 5, 2014, Pages 473-479

  Gooch, Jennifer L ^a   Sharma, Avadhesh C ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

anti IL 17; anti TNF ; calcineurin inhibitors; cardiovascular disease; hypertension; immunosuppression; inflammation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 17; INTERLEUKIN 6; ANTIHYPERTENSIVE AGENT; AUTACOID; CYTOKINE;

CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATION; MEDIATOR RELEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD PRESSURE; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYTOKINES; DRUG DESIGN; HUMANS; HYPERTENSION; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84906079595     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000052     Document Type: Review

References (63)

1. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104:545-556.
2. Esler MD, Krum H, Sobotka PA, et al. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): A randomised controlled trial. Lancet 2010; 376:1903-1909.
3. DiBona GF, Esler M. Translational medicine: The antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298:R245-R253.
4. Ramchandra R, Yao ST, May CN. Organ selective regulation of sympathetic outflow by the brain angiotensin system. Curr Hypertens Rep 2013; 15:401-408.
5. Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ 2014; 38:20-24.
6. Dikalov SI, Nazarewicz RR, Bikineyeva A, et al. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal 2014; 20:281-294.
7. Wu J, Thabet SR, Kirabo A, et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-Activated protein kinase. Circ Res 2014; 114:616-625.
8. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol 2007; 292:F330-F339.
9. De Miguel C, Guo C, Lund H, et al. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. Am J Physiol Renal Physiol 2011; 300:F734-F742.
10. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol V 298 2010; R1136-R1142.
11. De Ciuceis C, Amiri F, Brassard P, et al. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: Evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25:2106-2113.
12. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011; 124:1370-1381.
13. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460.
14. Crowley SD, Song YS, Lin EE, et al. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298:R1089-R1097.
15. Mattson DL, Lund H, Guo C, et al. Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renaldamage.Am J Physiol Regul Integr Comp Physiol 2013; 304:R407-R414.
16. Vinh A, Chen W, Blinder Y, et al. Inhibition and genetic ablation of the B7/ CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 2010; 122:2529-2537.
17. Okuda T,Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 1967; 25:257-264.
18. Olsen F. Transfer of arterial hypertension by splenic cells from DOCA-salt hypertensive and renal hypertensive rats to normotensive recipients. Acta Pathol Microbiol Scand C 1980; 88:1-5.
19. Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, cant live without. J Immunol 2013; 191:5785-5791.
20. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: Incidence, pathogenesis and management. Drug Saf 1999; 20:437-449.
21. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603-611.
22. Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev 2000; 80:1483-1521.
23. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004; 36 (Suppl 2):234S-239S.
24. Su Q, Weber L, Le Hir M, et al. Nephrotoxicity of cyclosporin A and FK506: Inhibition of calcineurin phosphatase. Ren Physiol Biochem 1995; 18:128-139.
25. Roullet JB, Xue H, McCarron DA, et al. Vascular mechanisms of cyclosporininduced hypertension in the rat. J Clin Invest 1994; 93:2244-2250.
26. Gooch JL. An emerging role for calcineurin Aalpha in the development and function of the kidney. Am J Physiol Renal Physiol 2006; 290:F769-F776.
27. Gooch JL, Guler RL, Barnes JL, Toro JJ. Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus. J Cell Sci 2006; 119 (Pt 12):2468-2476.
28. Gooch JL, Roberts BR, Cobbs SL, Tumlin JA. Loss of the alpha-isoform of calcineurin is sufficient to induce nephrotoxicity and altered expression of transforming growth factor-beta. Transplantation 2007; 83:439-447.
29. Pena JA, Losi-Sasaki JL, Gooch JL. Loss of calcineurin Aalpha alters keratinocyte survival and differentiation. J Invest Dermatol 2010; 130:135-140.
30. Van Raalte DH, Diamant M. Steroid diabetes: From mechanism to treatment? Neth J Med 2014; 72:62-72.
31. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 (Suppl 1):s2-8.
32. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47:85-118.
33. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001; 24:645-663.
34. Boesen EI, Williams DL, Pollock JS, Pollock DM. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol 2010; 37:1016-1022.
35. Spradley FT, De Miguel C, Hobbs J, et al. Mycophenolate mofetil prevents high-fat diet-induced hypertension and renal glomerular injury in Dahl SS rats. Physiol Rep 2013; 1:e00137. doi: 10.1002/phy2.137. [Epub ahead of print]
36. Tian N, Gu JW, Jordan S, et al. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007; 292:H1018-H1025.
37. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2006; 48:149-156.
38. Rodriguez-Iturbe B, Quiroz Y, Herrera-Acosta J, et al. The role of immune cells infiltrating the kidney in the pathogenesis of salt-sensitive hypertension. J Hypertens Suppl 2002; 20:S9-S14.
39. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006; 17 (12 Suppl 3):S218-S225.
40. Annunziato F, Cosmi L, Liotta F, et al. The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 2008; 20:1361-1368.
41. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008; 10:206-213.
42. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther 2010; 87:483-487.
43. Matsumoto K, Fukuda N, Abe M, Fujita T. Dendritic cells and macrophages in kidney disease. Clin Exp Nephrol 2010; 14:1-11.
44. Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol 2013; 2013:968549.
45. Wallace K, Morris R, Kyle PB, et al. Hypertension, inflammation and T lymphocytes are increased in a rat model of HELLP syndrome. Hypertens Pregnancy 2014; 33:41-54.
46. Lozovoy MA, Simao AN, Morimoto HK, et al. Hypertension is associated with serologically active disease in patients with systemic lupus erythematosus: Role of increased Th1/Th2 ratio and oxidative stress. Scand J Rheumatol 2014; 43:59-62.
47. Eid RE,RaoDA, Zhou J, et al. Interleukin-17 and interferon-gammaare produced concomitantly byhuman coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119:1424-1432.
48. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86:1154-1159.
49. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38:399-403.
50. Zhang W, Wang W, Yu H, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 2012; 59:136-144.
51. Lukic L, Lalic NM, Rajkovic N, et al. Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: Potential targets for an efficient preventive intervention. Int J Environ Res Public Health 2014; 11:3586-3598.
52. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-Alpha) and essential hypertension. J Hum Hypertens 2005; 19:149-154.
53. Nguyen H, Chiasson VL, Chatterjee P, et al. Interleukin-17 causes Rhokinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 2013; 97:696-704.
54. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin IIinduced hypertension and vascular dysfunction. Hypertension 2010; 55:500-507.
55. Liu W, Wang X, Feng W, et al. Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats. Exp Mol Pathol 2011; 91:362-367.
56. Brands MW, Banes-Berceli AK, Inscho EW, et al. Interleukin 6 knockout prevents angiotensin II hypertension: Role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 2010; 56:879-884.
57. Tran LT, MacLeod KM, McNeill JH. Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem 2009; 330:219-228.
58. Venegas-Pont M, Manigrasso MB, Grifoni SC, et al. Tumor necrosis factoralpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 2010; 56:643-649.
59. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: A systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73:529-535.
60. Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014; 70:168-177.
61. Brown G, Malakouti M, Wang E, et al. Anti-IL-17 phase II data for psoriasis: A review. J Dermatolog Treat 2014. [Epub ahead of print]
62. Paula FS, Alves JD. Nontumor necrosis factor-based biologic therapies for rheumatoid arthritis: Present, future, and insights into pathogenesis. Biologics 2014; 8:1-12.
63. Williams SC. Flurry of deal-making surrounds new autoimmunity target. Nat Med 2013; 19:1078.